# Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive Study Guide This study guide is designed to provide an exhaustive overview of the clinical practice guidelines for the prevention and management of Medication-Related Osteonecrosis of the Jaw (MRONJ) in patients with cancer. It synthesizes evidence-based recommendations and consensus-based expert opinions from the MASCC/ISOO and ASCO multidisciplinary panel. --- ## I. Core Concepts and Diagnostic Framework ### 1. Definition and Diagnostic Criteria MRONJ is a condition characterized by bone necrosis in the maxillofacial region associated with specific pharmacologic therapies. To establish a formal diagnosis, a clinician must confirm the presence of **all three** of the following criteria: 1. **Medication History:** Current or previous treatment with a bone-modifying agent (BMA) or an angiogenic inhibitor. 2. **Clinical Presentation:** Exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for longer than 8 weeks. 3. **Exclusionary Factors:** No history of radiation therapy to the jaws or metastatic disease to the jaws. ### 2. Associated Medications and Risk Profiles The primary medications linked to MRONJ are Bone-Modifying Agents (BMAs), specifically bisphosphonates and denosumab. The risk varies significantly based on the indication (oncologic vs. osteoporotic doses) and the specific agent used. **Table 1: Bone-Modifying Agents and MRONJ Risk in Oncology** | Medication | Route | Frequency of MRONJ | | :--- | :--- | :--- | | **Pamidronate** | IV | 3.2% – 5.0% | | **Zoledronic Acid** | IV | 1.0% – 8.0% (metastatic) / 0% – 1.8% (adjuvant) | | **Denosumab** | SC | 0.7% – 6.9% (metastatic) / 0% (adjuvant) | *Note: In metastatic settings, the patient-year adjusted incidence of confirmed ONJ for denosumab can reach 4.6% per year after the second year of treatment.* --- ## II. Risk Reduction and Prevention Strategies ### 1. Coordination of Care The cornerstone of MRONJ prevention is the multidisciplinary collaboration between the oncologist and the dental provider. * **Pre-Therapy Assessment:** For non-urgent cases, a comprehensive dental, periodontal, and radiographic exam should be completed before initiating BMA therapy. * **Dental Care Plan:** Medically necessary procedures (e.g., extractions of non-salvageable teeth) should be performed and the site allowed to achieve mucosal coverage before starting BMAs. * **Ongoing Monitoring:** Once BMA therapy commences, patients should receive routine dental follow-ups, typically every 6 months. ### 2. Modifiable Risk Factors Members of the care team must address factors that increase a patient's susceptibility to MRONJ: * **Oral Health:** Poor oral hygiene and periodontal disease. * **Mechanical Factors:** Ill-fitting dentures and invasive dental procedures. * **Systemic Factors:** Uncontrolled diabetes mellitus and tobacco use. * **Cofactors:** Use of corticosteroids, chemotherapy, or angiogenic inhibitors. ### 3. Dentoalveolar Surgery Protocols * **Elective Surgery:** Procedures such as non-medically necessary extractions or implants should be avoided during active BMA therapy at oncologic doses. * **Invasive Procedures:** If surgery is necessary, it should be performed by a specialist. Post-operative follow-up should occur every 6 to 8 weeks until full mucosal coverage is achieved. * **BMA Discontinuation:** There is currently insufficient evidence to support or refute the temporary discontinuation of BMAs (a "drug holiday") before surgery. This decision remains at the clinician's discretion. --- ## III. Staging and Outcome Measures ### 1. Staging Systems Clinicians should use a consistent staging system (such as the AAOMS or CTCAE 5.0) to quantify the severity of the disease. **Table 2: AAOMS Staging Overview** | Stage | Description | | :--- | :--- | | **At Risk** | No apparent necrotic bone; treated with BMAs. | | **Stage 0** | No clinical evidence of necrotic bone, but non-specific clinical/radiographic findings and symptoms (e.g., bone pain, altered sensation). | | **Stage 1** | Exposed/necrotic bone or fistulas; asymptomatic; no sign of infection. | | **Stage 2** | Exposed/necrotic bone or fistulas associated with infection (pain, erythema, purulent drainage). | | **Stage 3** | Exposed/necrotic bone with infection and complications (pathologic fracture, extraoral fistula, or osteolysis extending to the inferior border). | ### 2. Clinical Outcome Terms To facilitate interprofessional communication, the status of MRONJ lesions should be described using the following terms: * **Resolved:** Complete mucosal healing; no pain or infection; radiographic improvement. * **Improving:** Significant improvement (>50% mucosal coverage, >50% pain reduction, or no signs of infection). * **Stable:** Mild improvement (<50% mucosal coverage or pain reduction). * **Progressive:** No improvement or worsening of symptoms and radiographic signs. --- ## IV. Management Approaches ### 1. Initial Treatment (Conservative) Conservative measures are the preferred first-line approach for all stages of MRONJ: * **Antimicrobial Rinses:** Use of 0.12% chlorhexidine or similar agents. * **Antibiotics:** Systemic therapy if clinical infection is present. * **Conservative Surgery:** Removal of superficial bone spicules that cause soft tissue irritation. * **Pain Management:** Use of analgesics as indicated. ### 2. Refractory Management (Aggressive) Aggressive surgical interventions (e.g., mucosal flap elevation, block resection, or jaw reconstruction) are reserved for cases that: * Result in persistent symptoms despite conservative care. * Significantly affect oral function. * Note: Aggressive surgery is **not** recommended for asymptomatic bone exposure. --- ## V. Short-Answer Practice Questions 1. **What is the minimum duration that bone exposure must persist to meet the definition of MRONJ?** * *Answer:* The exposure or fistula must persist for longer than 8 weeks. 2. **Which two classes of medications are explicitly mentioned in the diagnostic criteria for MRONJ?** * *Answer:* Bone-modifying agents (BMAs) and angiogenic inhibitors. 3. **Why is "Stage 0" a controversial designation in some staging systems?** * *Answer:* Critics argue it may lead to overdiagnosis, as the symptoms (bone pain, radiographic changes) overlap with chronic periodontal disease, potentially leading to the unnecessary discontinuation of vital BMA therapy. 4. **According to the MASCC/ISOO daily oral care plan, what are the components of a "bland rinse"?** * *Answer:* A mixture of 1 teaspoon of salt and 1 teaspoon of baking soda in 4 cups of water. 5. **Under what circumstances should aggressive surgical intervention be considered?** * *Answer:* When MRONJ results in persistent symptoms or affects function despite initial conservative treatment, and after a thorough discussion of risks and benefits with the multidisciplinary team. --- ## VI. Essay Prompts for Deeper Exploration 1. **The Multidisciplinary Paradigm:** Analyze the roles of the oncologist, general dentist, and dental specialist in the management of a patient starting BMA therapy. How does coordination between these entities impact patient outcomes and the prevention of MRONJ? 2. **Risk-Benefit Analysis of BMA Discontinuation:** Discuss the clinical dilemma regarding the "drug holiday." Evaluate the potential benefits of BMA discontinuation for MRONJ resolution versus the risks of skeletal-related events (SREs) such as fractures and hypercalcemia. 3. **The Impact of Modifiable Factors:** Examine how systemic conditions like diabetes and lifestyle choices like tobacco use exacerbate the risk of MRONJ. Propose a patient education strategy to address these factors early in the oncologic treatment course. --- ## VII. Glossary of Important Terms * **Angiogenic Inhibitor:** A type of medication that interferes with the growth of new blood vessels, sometimes associated with the development of MRONJ. * **Alveoloplasty:** A surgical procedure used to smooth or reshape the jawbone, typically after tooth extraction. * **Bone-Modifying Agent (BMA):** A class of drugs (including bisphosphonates and denosumab) used to reduce skeletal-related events in cancer patients with bone metastases. * **Dentoalveolar Surgery:** Surgical procedures involving the teeth and the contiguous alveolar bone. * **Extraoral Fistula:** An abnormal passage leading from the bone or an internal cavity to the outside of the skin on the face or neck. * **Maxillofacial:** Relating to the jaws and face. * **Osteoradionecrosis:** Bone necrosis caused specifically by radiation therapy, which must be ruled out to diagnose MRONJ. * **Sequestrectomy:** The surgical removal of a sequestrum. * **Sequestrum (Sequestra):** A piece of dead bone that has become detached during the process of necrosis from the sound bone. * **Skeletal-Related Event (SRE):** Clinical complications of bone metastases, including pathologic fractures, spinal cord compression, or the need for radiation/surgery to the bone.